Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Genmab Ord Shs GNMSF

Healthcare Biotechnology
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA... see more

Recent & Breaking News (OTCPK:GNMSF)

Genmab to Receive $3 Million Milestone Payment in DuoBody Platform Collaboration with Janssen

GlobeNewswire December 12, 2014

Genmab Announces Phase II Study of Daratumumab in Non-Hodgkin's Lymphomas

GlobeNewswire December 4, 2014

Genmab Announces Phase II Study of Daratumumab in Smoldering Multiple Myeloma

GlobeNewswire November 24, 2014

Genmab Announces New Phase III Combination Study of Daratumumab in Frontline Multiple Myeloma

GlobeNewswire November 10, 2014

Genmab Announces Daratumumab and Ofatumumab Data to Be Presented at American Society of Hematology Annual Meeting (ASH)

GlobeNewswire November 6, 2014

Genmab Announces Additional Data from Phase III Study of Ofatumumab as Maintenance Therapy for Relapsed CLL

GlobeNewswire November 6, 2014

Genmab Announces Financial Results for the First Nine Months of 2014

GlobeNewswire November 5, 2014

Genmab Announces Conditional Transfer of Ofatumumab Agreement

GlobeNewswire November 3, 2014

Genmab Reaches USD 10 Million Milestone in Daratumumab Collaboration with Janssen

GlobeNewswire October 23, 2014

Third Quarter 2014 Net Sales Figures for Arzerra(r)

GlobeNewswire October 22, 2014

Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration

GlobeNewswire September 10, 2014

Major Shareholder Announcement

GlobeNewswire August 25, 2014

Genmab Announces Financial Results for the First Half of 2014 and Improves 2014 Financial Guidance

GlobeNewswire August 13, 2014

Genmab Announces New Phase III Study of Daratumumab in Front Line Multiple Myeloma

GlobeNewswire August 11, 2014

GSK and Genmab Announce Positive Interim Result for Phase III Study of Ofatumumab as Maintenance Therapy for Relapsed CLL

GlobeNewswire July 31, 2014

Second Quarter 2014 Net Sales Figures for Arzerra(r)

GlobeNewswire July 23, 2014

Genmab Announces Phase III Study of Daratumumab in Front Line Multiple Myeloma

GlobeNewswire July 18, 2014

Genmab to Receive Milestone Payment in DuoBody Platform Collaboration with Janssen

GlobeNewswire July 14, 2014

Genmab Reaches USD 25 Million Milestone in Daratumumab Collaboration with Janssen

GlobeNewswire July 7, 2014

GSK and Genmab Receive EU Authorization for Arzerra(tm) (ofatumumab) as First-Line Treatment for Chronic Lymphocytic Leukemia (CLL) in Combination with Chlorambucil or Bendamustine for Patients Ineligible for Fludarabine-based Therapy

GlobeNewswire July 3, 2014